T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Astec Industries
ASTE
$994M
| $1.18M | ﹤0.01% |
27,102
+977
| +4% | +$44.6K |
|
2002
Cohu
COHU
$2.76B
| $1.18M | ﹤0.01% |
50,490
+1,831
| +4% | +$42K |
|
|
VG
2003
Venture Global Inc
VG
$33.9B
| $1.17M | ﹤0.01% |
171,173
+26,300
| +18% | +$219K |
|
|
PPTA
2004
Perpetua Resources
PPTA
$3.1B
| $1.17M | ﹤0.01% |
48,174
+7,736
| +19% | +$190K |
|
2005
Cimpress
CMPR
$2.4B
| $1.16M | ﹤0.01% |
17,468
+1,687
| +11% | +$114K |
|
2006
V2X
VVX
$2.55B
| $1.16M | ﹤0.01% |
21,285
+3,375
| +19% | +$190K |
|
2007
Capitol Federal Financial
CFFN
$1.1B
| $1.16M | ﹤0.01% |
170,451
+5,262
| +3% | +$34.2K |
|
|
DX
2008
Dynex Capital
DX
$3.23B
| $1.16M | ﹤0.01% |
82,828
+13,163
| +19% | +$178K |
|
|
ARI
2009
Apollo Commercial Real Estate
ARI
$885M
| $1.16M | ﹤0.01% |
119,577
+6,181
| +5% | +$61.8K |
|
2010
HCI Group
HCI
$2.28B
| $1.16M | ﹤0.01% |
6,021
+492
| +9% | +$92.7K |
|
2011
AvePoint
AVPT
$2.91B
| $1.15M | ﹤0.01% |
82,861
+11,833
| +17% | +$163K |
|
2012
Worthington Steel
WS
$1.94B
| $1.14M | ﹤0.01% |
32,950
+1,409
| +4% | +$46.3K |
|
2013
Metallus
MTUS
$900M
| $1.14M | ﹤0.01% |
66,294
+2,117
| +3% | +$36.3K |
|
|
TIC
2014
TIC Solutions Inc
TIC
$2.22B
| $1.14M | ﹤0.01% |
112,544
+19,046
| +20% | +$212K |
|
2015
Innodata
INOD
$2.03B
| $1.14M | ﹤0.01% |
22,295
-241,191
| -92% | -$15.7M |
|
|
PDM
2016
Piedmont Realty Trust
PDM
$1.19B
| $1.13M | ﹤0.01% |
135,685
+2,534
| +2% | +$21.2K |
|
2017
Carter's
CRI
$1.43B
| $1.13M | ﹤0.01% |
34,763
-1,837
| -5% | -$57.4K |
|
|
AVDL
2018
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.12M | ﹤0.01% |
51,970
+3,392
| +7% | +$65.9K |
|
2019
Willdan Group
WLDN
$1.29B
| $1.12M | ﹤0.01% |
10,795
+730
| +7% | +$71.9K |
|
2020
Gorman-Rupp
GRC
$2.15B
| $1.12M | ﹤0.01% |
23,397
+702
| +3% | +$32.7K |
|
2021
Centuri Holdings
CTRI
$2.4B
| $1.11M | ﹤0.01% |
44,152
+6,489
| +17% | +$145K |
|
|
AHRT
2022
AH Realty Trust
AHRT
$501M
| $1.11M | ﹤0.01% |
168,063
+60,101
| +56% | +$397K |
|
2023
Vishay Precision Group
VPG
$908M
| $1.11M | ﹤0.01% |
28,871
-2,270
| -7% | -$80.3K |
|
|
DHC
2024
Diversified Healthcare Trust
DHC
$2.02B
| $1.11M | ﹤0.01% |
228,944
+7,578
| +3% | +$34.4K |
|
2025
G-III Apparel Group
GIII
$1.41B
| $1.11M | ﹤0.01% |
38,258
-2,972
| -7% | -$84.9K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.